Persistence and Fitness of Multidrug-Resistant Human Immunodeficiency Virus Type 1 Acquired in Primary Infection
暂无分享,去创建一个
Bluma G. Brenner | M. Wainberg | B. Brenner | D. Moisi | B. Spira | B. Conway | J. Routy | R. Sékaly | R. Lalonde | Rafick-Pierre Sekaly | Brian Conway | Mark A. Wainberg | Maureen Oliveira | Daniela Moisi | Jean-Pierre Routy | Richard Lalonde | Maureen Oliveira | Marco Petrella | Mervi Detorio | Bonnie Spira | Vidal Essabag | M. Detorio | M. Petrella | Vidal Essabag
[1] M. Youle,et al. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. , 1999, AIDS.
[2] M. Wainberg,et al. Comparison of cord blood and peripheral blood mononuclear cells as targets for viral isolation and drug sensitivity studies involving human immunodeficiency virus type 1 , 1994, Journal of clinical microbiology.
[3] B Clotet,et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. , 1998, JAMA.
[4] R Hoh,et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. , 2001, The New England journal of medicine.
[5] S. Frost,et al. Evolution of Lamivudine Resistance in Human Immunodeficiency Virus Type 1-Infected Individuals: the Relative Roles of Drift and Selection , 2000, Journal of Virology.
[6] C. Verhofstede,et al. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. , 1999, AIDS.
[7] P. Harrigan,et al. Relative Replicative Fitness of Zidovudine-Resistant Human Immunodeficiency Virus Type 1 Isolates In Vitro , 1998, Journal of Virology.
[8] L. Stuyver,et al. Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene , 1997, Antimicrobial agents and chemotherapy.
[9] J. Cherrington,et al. Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro. , 1999, The Journal of infectious diseases.
[10] E. Rosenberg,et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. , 1999, JAMA.
[11] E. De Clercq,et al. Baseline HIV type 1 genotypic resistance to a newly added nucleoside analog is predictive of virologic failure of the new therapy. , 2000, AIDS research and human retroviruses.
[12] Y. Cao,et al. HIV-1 drug resistance in newly infected individuals. , 1999, JAMA.
[13] Michael A. Parniak,et al. Effectiveness of 3TC in HIV clinical trials may be due in part to the M184V substitution in 3TC‐resistant HIV‐1 reverse transcriptase , 1996, AIDS.
[14] Roy E. Byington,et al. Quantitative Assays for Virus Infectivity , 1990 .
[15] J. Pitt,et al. Selective vertical transmission of HIV‐1 antiretroviral resistance mutations , 1998, AIDS.
[16] J. Schapiro,et al. Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trial , 1999, The Lancet.
[17] B. Schmidt,et al. Selective vertical transmission of HIV: lamivudine-resistant maternal clone undetectable by conventional resistance testing. , 1999, AIDS.
[18] C. Crumpacker,et al. Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation , 1997, Journal of virology.
[19] Wilco Keulen,et al. Estimating Relative Fitness in Viral Competition Experiments , 2000, Journal of Virology.
[20] M. Wainberg,et al. Changes in natural immunity during the course of HIV‐1 infection , 1993, Clinical and experimental immunology.
[21] J. Kahn,et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. , 1998, The New England journal of medicine.
[22] T. Merigan,et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy , 2000 .
[23] E. Arts,et al. A Dual Infection/Competition Assay Shows a Correlation between Ex Vivo Human Immunodeficiency Virus Type 1 Fitness and Disease Progression , 2000, Journal of Virology.
[24] S. Yerly,et al. Transmission of antiretroviral-drug-resistant HIV-1 variants , 1999, The Lancet.
[25] Guy Burtonboy,et al. Comparison of DNA Sequencing and a Line Probe Assay for Detection of Human Immunodeficiency Virus Type 1 Drug Resistance Mutations in Patients Failing Highly Active Antiretroviral Therapy , 2001, Journal of Clinical Microbiology.
[26] M. Wainberg,et al. Public health implications of antiretroviral therapy and HIV drug resistance. , 1998, JAMA.
[27] J. Pagano,et al. Long-term persistence of zidovudine resistance mutations in plasma isolates of human immunodeficiency virus type 1 of dideoxyinosine-treated patients removed from zidovudine therapy. , 1994, The Journal of infectious diseases.
[28] C. Boucher,et al. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. , 1999, AIDS.
[29] J. Martinez-Picado,et al. Replicative Fitness of Protease Inhibitor-Resistant Mutants of Human Immunodeficiency Virus Type 1 , 1999, Journal of Virology.
[30] M A Wainberg,et al. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use , 2000, AIDS.
[31] J. Coffin,et al. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy , 1995, Science.
[32] S. Plaeger,et al. Perinatal Transmission of Major, Minor, and Multiple Maternal Human Immunodeficiency Virus Type 1 Variants In Utero and Intrapartum , 2001, Journal of Virology.
[33] J. Schapiro,et al. Persisting Long-Term Benefit of Genotype-Guided Treatment for HIV-Infected Patients Failing Haart. The Viradapt Study: Week 48 Follow-Up , 2000, Antiviral therapy.